Generation Bio Co
XNAS:GBIO 4:00:00 PM EDT
| Market Cap (Intraday) | 35.49M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.76 |
| 50-Day MA | $6.03 |
| 200-Day MA | $5.20 |
Generation Bio Co Stock, XNAS:GBIO
301 Binney Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.655.7500
Number of Employees: 115
Description
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.